Incidence of myocarditis/pericarditis following mRNA COVID-19 vaccination among children, younger adults in the US

booster

In a population-based surveillance published in the Annals of Internal Medicine, the authors found that myocarditis/pericarditis 0 to 7 days after mRNA vaccination in persons aged 5 to 39 years occurred in approximately 1 in 200,000 doses after the first dose and 1 in 30,000 doses after the second dose of the primary series, and 1 in 50,000 doses after the first booster. The incidence varied markedly by age and sex, however, with a disproportionate number of cases occurring in male persons, notably among adolescents after dose 2 and first boosters.

The authors observed incidence after first boosters was generally higher than after dose 1, consistent with reporting from Israel. However, in contrast to this earlier report, they did not consistently observe a lower incidence after the first booster than after the second dose in the primary vaccination series. Incidence rates of myocarditis/pericarditis observed in the VSD population were higher, particularly after first boosters, than those reported to the U.S. Vaccine Adverse Event Reporting System (VAERS), but patterns noted by sex and age subgroups were similar.

Source: Read Full Article